<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181437</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1203_DDI</org_study_id>
    <nct_id>NCT04181437</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2</brief_title>
  <acronym>Navipharm</acronym>
  <official_title>A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interaction and Safety Between NVP-1203-R1 and NVP-1203-R2 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety between NVP-1203-R1
      and NVP-1203-R2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      pharmacokinetics and safety between NVP-1203-R1 and NVP-1203-R2
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2020</start_date>
  <completion_date type="Anticipated">July 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interaction</measure>
    <time_frame>0hours - 24hours</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1203-R1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1203-R1
1 tablet, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1203-R2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1203-R2
1 tablet, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1203-R1 and NVP-1203-R2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1203-R1 1 tablet and NVP-1203-R2 1 tablet co-administration(oral dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R1</intervention_name>
    <description>1 tablet, Single oral dosing</description>
    <arm_group_label>NVP-1203-R1</arm_group_label>
    <other_name>NVP-1203-R1(A)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R2</intervention_name>
    <description>1 tablet, Single oral dosing</description>
    <arm_group_label>NVP-1203-R2</arm_group_label>
    <other_name>NVP-1203-R2(E)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1203-R1 and NVP-1203-R2</intervention_name>
    <description>NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing</description>
    <arm_group_label>NVP-1203-R1 and NVP-1203-R2</arm_group_label>
    <other_name>NVP-1203-R1(A) and NVP-1203-R2(E)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adult subjects who signed informed consent

        Exclusion Criteria:

          -  Subjects has a history of allergy reaction of study drug ingredient

          -  Subjects participated in another clinical trial within 6 months prior to
             administration of the study drug

          -  Inadequate subject for the clinical trial by the investigator's decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon Y Ran, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hye Rim Lim</last_name>
    <phone>+82-31-547-9781</phone>
    <email>hrlim@navipharm.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Dongdeok-ro</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>November 27, 2019</last_update_submitted>
  <last_update_submitted_qc>November 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

